Physician profile
Daniel P Chafetz
NPI 1932130887
$18,206.35
in general payments reported to CMS, 2019-2025
36 companies · $3,921 in 2025
The $3,921 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,748 · 2022: $3,086 · 2023: $3,703 · 2024: $3,749 · 2025: $3,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $707 · Education: $49.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,615.41 |
| Travel and Lodging | $706.84 |
| Education | $49.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,547.48 | 2021-2025 | Abilify Mycite, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $3,117.91 | 2021-2025 | |
| Neuronetics, INC. | $1,854.30 | 2023-2024 | Neurostar Tms Therapy System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,476.86 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,444.05 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $1,299.57 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $1,002.50 | 2021-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $578.06 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Janssen Pharmaceuticals, INC | $553.96 | 2022-2025 | Spravato, Invega Sustenna, Invega |
| Sunovion Pharmaceuticals INC. | $455.69 | 2021-2022 | |
| Bausch Health US, LLC | $398.87 | 2021-2025 | Aplenzin |
| Indivior INC. | $312.39 | 2021-2025 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $258.78 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $247.08 | 2024-2025 | Qelbree |
| Harmony Biosciences LLC | $208.12 | 2022-2024 | Wakix |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $158.71 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $155.26 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $146.01 | 2021-2025 | Trintellix |
| Pfizer INC. | $144.95 | 2023-2025 | |
| Avanir Pharmaceuticals, INC. | $107.27 | 2021-2022 | |
| Alfasigma USA, INC. | $101.66 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $101.11 | 2024 | Ingrezza |
| Amgen INC. | $95.95 | 2021 | |
| Corium, LLC | $78.04 | 2023-2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $64.05 | 2021 | |
| Idorsia Pharmaceuticals US INC | $61.04 | 2023-2024 | Quviviq |
| Eisai INC. | $47.91 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $36.49 | 2021 | |
| Allergan, INC. | $26.70 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $25.72 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.54 | 2022 | |
| Braeburn INC. | $22.16 | 2025 | Brixadi |
| Biohaven Pharmaceutical Holding Company LTD. | $15.14 | 2022 | |
| Lilly USA, LLC | $14.16 | 2022 | |
| Adlon Therapeutics L.P. | $12.03 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Chafetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.